Skip to main content
SpringerLink
Log in

Treatment of Extensive Stage Small Cell Lung Cancer

  • Chapter
Thoracic Oncology

Part of the book series: Cancer Treatment and Research ((CTAR,volume 105))

Abstract

Thymomas and thymic carcinomas are unique tumors of the anterior mediastinum. The association of a variety of different paraneoplastic syndromes with such lesions has fascinated physicians and researchers for years. Most recently, it has been demonstrated by numerous authors that thymomas are chemosensitive tumors. Their indolent nature and relative rarity have made evaluation through prospective randomized clinical trials extremely difficult. Further information regarding the molecular nature of these neoplasms and immunologic aspects is needed in future investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cook RM, Miller YE, Bunn PA Jr. Small cell lung cancer: Etiology, biology, clinical features, staging and treatment. Current Problems in Cancer 17(2):69144, 1993.

    Article  Google Scholar 

  2. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA: A Cancer Journal for Clinicians 50:7–33, 2000.

    Article  CAS  Google Scholar 

  3. Evans WK, Feld R, Murray N, et al. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Annals of Internal Medicine 107(4):451–458, 1987.

    PubMed  CAS  Google Scholar 

  4. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10:282–291, 1992.

    PubMed  CAS  Google Scholar 

  5. Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83:855–861, 1991.

    Article  PubMed  CAS  Google Scholar 

  6. Bunn PA Jr and Carney DN. Overview of chemotherapy for small cell lung cancer. Seminars in Oncology 24(2, Suppl 7):S7–69-S7–74, 1997.

    Google Scholar 

  7. Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 12:2022–2034, 1994.

    PubMed  CAS  Google Scholar 

  8. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 326(4):269–270, 1992.

    Article  Google Scholar 

  9. Murray N, Livingston RB, Shepherd FA, et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: An intergroup study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 17:2300–2308, 1999.

    PubMed  CAS  Google Scholar 

  10. Furuse K, Fukuoka M, Nishiwaki Y, et al. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. J Clin Oncol 16:2126–2132, 1998.

    PubMed  CAS  Google Scholar 

  11. Bunn PA Jr. Review of therapeutic trials of carboplatin in lung cancer. Semin Oncol 16:27–33, 1989.

    PubMed  Google Scholar 

  12. Skarlos DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin versus etoposide-carboplatin and irradiation in small cell lung cancer. A Hellenic Co-operative Oncology Group Study. Ann Oncol 5:601–607, 1994.

    PubMed  CAS  Google Scholar 

  13. Loehrer PJ Sr, Ansari R, Gonin R, et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: A Hoosier Oncology Group study. J Clin Oncol 13:2594–2599, 1995.

    PubMed  CAS  Google Scholar 

  14. Ettinger DS, Finkelstein DM, Abeloff MD, et al. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: A phase III study of the Eastern Cooperative Oncology Group. J Clin Oncol 8(2):230–240, 1990.

    PubMed  CAS  Google Scholar 

  15. Jarry O, Fournel P. A randomised trial of 4 versus 8 courses of chemotherapy with ifosfamide, epirubicin and etoposide (EVI) in extensive small cell lung cancer (SCLC). IASLC-SCLC: Denver CO, 1994 (abstr).

    Google Scholar 

  16. Sandler AB, Ansari R, Saxman S, et al. Phase III trial of maintenance daily oral VP-16 versus no further therapy following induction chemotherapy with VP-16 (V) plus ifosfamide (I) plus cisplatin (P) (VIP) in extensive small cell lung cancer (SCLC): A Hoosier Oncology Group (HOG) trial (LUN93–2). Proc Am Soc Clin Oncol 18:470a, 1999 (abstr 1813).

    Google Scholar 

  17. Chute JP, Chen T, Feigal E, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: Perceptible progress. J Clin Oncol 17(6):1794–1801, 1999.

    PubMed  CAS  Google Scholar 

  18. Rowinsky EK, Grochow LB, Hendricks CB, et al. Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 10(4):647–656, 1992.

    PubMed  CAS  Google Scholar 

  19. Schiller JH, Kim KM, Hufson P, et al. Phase II study of topotecan in patients with extensive-stage small cell carcinoma of the lung: An Eastern Cooperative Oncology Group trial. J Clin Oncol 14(8):2345–2352, 1996.

    PubMed  CAS  Google Scholar 

  20. Watanabe K,Fukuoka M,Niitani H for the Topotecan Lung Cancer Cooperative Study Group, Japan. Phase II trial of topotecan for small cell lung cancer (SCLC). Lung Cancer 1997:18:58 (abstract).

    Article  Google Scholar 

  21. Depierre A, von Pawel J, Hans K, et al, international study collaborators, SmithKline Beecham, UK. Evaluation of topotecan (HycamtinTM) in relapsed small cell lung cancer (SCLC). A multicentre phase II study. Lung Cancer 18:35, 1997 (abstract).

    Article  Google Scholar 

  22. Ardizzoni A, Hansen H, Dombernowsky P, et al for the European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. J Clin Oncol 1997: 15(5):2090–2096.

    PubMed  CAS  Google Scholar 

  23. Nishiwaki Y, Negoro S, Watanabe K, et al. Late phase II trials of topotecan (T) for relapsed small cell lung cancer (SCLC). European Journal of Cancer 35(Suppl 4) S253, 1999 (abstract 1004).

    Article  Google Scholar 

  24. Perez-Soler R, Glisson BS, Lee JS, et al. Phase II study of topotecan in patients with small cell lung cancer (SCLC) refractory to etoposide. Proc Am Soc Clin Oncol 14:355 (abstract) 1995.

    Google Scholar 

  25. von Pawel J, Schiller JH, Shepherd FA. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17(2):658–667, 1999.

    Google Scholar 

  26. Eckardt J, Palmer MC, Fanucchi M, et al. Oral topotecan (T) as single-agent first-line treatment for patients (pts) with extensive disease (ED) small cell lung cancer (SCLC) ineligible for standard IV therapy: A phase II study. Proc Am Soc Clin Oncol 18:501a, 1999 (abstract 1925).

    Google Scholar 

  27. Korfel A, von Pawel J, Oehm E, et al. Response of symptomatic brain metastases of small cell lung cancer (SCLC) to topotecan also after preceeding whole-brain radiation (WBI). European Journal of Cancer 35(Suppl 4) S251, 1999 (abstract 997).

    Article  Google Scholar 

  28. Jacobs SA, Jett JR, Belani CP, et al. Topotecan and paclitaxel, an active couplet, in untreated extensive disease small cell lung cancer. Proc Am Soc Clin Oncol 18:470a, 1999 (abstract 1814).

    Google Scholar 

  29. Tweedy CR, Andrews DF, Ball T. Topotecan and paclitaxel in extensive stage small cell lung cancer as initial therapy. Proc Am Soc Clin Oncol 18:525a, 1999 (abstract 2025).

    Google Scholar 

  30. Panza N, Frasci G, Comella P, et al. Cisplatin-paclitaxel-topotecan (CPT) weekly administration in chemo-naïve or pretreated extensive disease small cell lung cancer (ED-SCLC). A SICOG phase II study. European Journal of Cancer 35(Suppl 4) S252, 1999 (abstract 1001).

    Article  Google Scholar 

  31. Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH. Phase II study of paclitaxel in patients with extensive disease small cell lung cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 13:1430–1435, 1995.

    PubMed  CAS  Google Scholar 

  32. Kirschling RJ, Jung SH, Jett JR for the North Central Cancer Treatment Group. A phase II trial of taxol and G-CSF in previously untreated patients with extensive-stage small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 13:326, 1994 (abstract).

    Google Scholar 

  33. Nair S, Marschke R, Grill J, et al. A phase II study of paclitaxel (Taxol®) and cisplatin (CDDP) in the treatment of extensive stage small cell lung cancer (ESSCLC). Proc Am Soc Clin Oncol 16:454a (abstract), 1997.

    Google Scholar 

  34. Lyss AP, Herndon JE, Lynch TC, et al. Paclitaxel (P) + Cisplatin (C) + G-CSF (G) in patients with previously untreated extensive stage small cell lung cancer (ESCLC): Preliminary analysis of Cancer and Leukemia Group B (CALGB) 9430. Proc Am Soc Clin Oncol 18:468a, 1999 (abstract 1806).

    Google Scholar 

  35. Glisson BS, Kurie JM, Perez-Soler R, et al. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. J Clin Oncol 17:2309–2315, 1999.

    PubMed  CAS  Google Scholar 

  36. Kelly K, Pan Z, Wood ME, et al. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer. Clinical Cancer Research 5:3419–3424, 1999.

    PubMed  CAS  Google Scholar 

  37. Bunn PA, Kelly K, Crowley J, et al. Preliminary toxicity results from Southwest Oncology Group trial (SWOG) 9705: A phase II trial of cisplatin, etoposide and paclitaxel (PET) with G-CSF in untreated patients (pts) with extensive small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 18:468a, 1999 (abstract 1807).

    Google Scholar 

  38. Mavroudis D, Papadakis E, Veselemes M, et al. Paclitaxel-cisplatin-etoposide (TEP) versus cisplatin-etoposide (EP) as first line treatment in small cell lung cancer (SCLC): A preliminary analysis of a multicenter randomized phase III trial. European Journal of Cancer 35(Suppl 4) S247, 1999 (abstract 980).

    Article  Google Scholar 

  39. Hainsworth JD, Gray JR, Stroup SL, et al. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: Comparison of sequential phase II trials using different dose-intensities. J Clin Oncol 15:3464–3470, 1997.

    PubMed  CAS  Google Scholar 

  40. Hainsworth JD, Niell HB. Taxol (paclitaxel) injection, carboplatin and etoposide in the management of small cell lung cancer: Clinical update. Princeton, NJ, Bristol-Myers Squibb, 1999.

    Google Scholar 

  41. Thomas P, Lena H, Robinet, et al. Preliminary report on paclitaxel/carboplatin phase II multicentric trial in patients with metastatic small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 18:519a, 1999 (abstract 2000).

    Google Scholar 

  42. Depperman KM, Serke M, Oehm C, et al. Paclitaxel (TAX) and carboplatin (CBDA) in advanced SCLC: A phase II study. Proc Am Soc Clin Oncol 18:482a, 1999 (abstract 1860).

    Google Scholar 

  43. Agelaki S, Agelidou M, Blazogiannakis G, et al. A phase II study of paclitaxel (P) and carboplatin (C) as second-line treatment in patients (PTS) with small-cell lung cancer (SCLC). European Journal of Cancer 35(Suppl 4) S258, 1999 (abstract 1027).

    Article  Google Scholar 

  44. Lad T, Mauer A, Hoffman P, et al. Phase II trial of paclitaxel and doxorubicin in small cell lung cancer. Proc Am Soc Clin Oncol 18:513a, 1999 (abstract 1980).

    Google Scholar 

  45. Burris HA, Crowley JJ, Williamson SK, et al. Docetaxel (taxotere) in extensive stage small cell lung cancer (SCLC): A phase II trial of the Southwest Oncology Group (SWOG). Proc Am Soc Clin Oncol 17:451a, 1998 (abstract 1737).

    Google Scholar 

  46. Smyth JF, Smith IE, Sessa C, et al. Activity of docetaxel (taxotere) in small cell lung cancer. Eur J Cancer (suppl):30A:1058–1060, 1994.

    Article  CAS  Google Scholar 

  47. Lianes P, Moreno JA, Sevilla I, et al. Phase II study of docetaxel and cisplatin in first line treatment of disseminated small cell lung cancer (SCLC): Preliminary results. Proc Am Soc Clin Oncol 18:514a, 1999 (abstract 1983).

    Google Scholar 

  48. Depierre A, LeChevalier T, Quoix E, et al. Phase II trial of navelbine (NVB) in small cell lung cancer (SCLC). Lung Cancer 18 (Suppl 1):3, 1997 (abstract).

    Google Scholar 

  49. Tummarello D, Graziano F, Giodani P. A phase II study of vinorelbine (VNB) in small cell lung cancer (SCLC) patients (PTS) unsuitable for standard chemotherapy (CHT). Proc Am Soc Clin Oncol 14:369, 1995 (abstract).

    Google Scholar 

  50. Furuse K, Fukuoka M, Kimura I, et al. Early phase II study of vinorebine (VRB) in small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 14:371, 1995 (abstract).

    Google Scholar 

  51. Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe C, et al. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. Eur J Cancer 29A(12):1720–1722, 1993.

    Article  PubMed  CAS  Google Scholar 

  52. Lake D, Johnson E, Herndon J, Green M. Phase II trial of Navelbine®(NVB) in relapsed small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 16:473a, 1997 (abstract).

    Google Scholar 

  53. Richardet E, Carranza L, Uribe A, et al. Phase II study: Cisplatin (C) + etoposide (E) + navelbine (N) in small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 14:373, 1995 (abstract 1151).

    Google Scholar 

  54. Gridelli C, Ianniello G, Brancaccio L, et al. Carboplatin plus vinorelbine: A new active regimen in extensive small cell lung cancer. Results of a multicenter phase II study. Lung Cancer 18 (suppl):55, 1997 (abstract 212).

    Article  Google Scholar 

  55. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10(8):1225–1229, 1992.

    PubMed  CAS  Google Scholar 

  56. Negoro S, Fukuoka M, Niitani H, et al. A phase II study of CPT-11, a campothecin derivative in patients with primary lung cancer. Gan to Kagaku Ryoho (Japanese Journal of Cancer and Chemotherapy) 18(6):1013–1019, 1991.

    CAS  Google Scholar 

  57. LeChevalier T, Ibrahim N, Chorny P, et al. A phase II study of irinotecan (CPT-11) in patients (pts) with small cell lung cancer (SCLC) progressing after initial response to first-line chemotherapy (CT). Proc Am Soc Clin Oncol 16:450a,1997 (abstract).

    Google Scholar 

  58. Nishio M, Karato A, Okumura S, et al. Second-line CPT-11 may improve survival in small cell lung cancer. European Journal of Cancer 35(Suppl 4) S261, 1999 (abstract 1038).

    Article  Google Scholar 

  59. Kudoh S, Fujiwara Y, Takada Y, et al. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol 16(3):1068–1074, 1998.

    PubMed  CAS  Google Scholar 

  60. Nakamura S, Kudoh S, Komuta K, et al. Phase II study of irinotecan (CPT-11) combined with etoposide (VP-16) for previously untreated extensive-disease small-cell lung cancer (ED-SCLC): A study of the West Japan Lung Cancer Group. Proc Am Soc Clin Oncol 18:470a, 1999 (abstract 1815).

    Google Scholar 

  61. Cormier Y, Eisenhauer E, Muldal A, et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC): National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 5:283–285, 1994.

    PubMed  CAS  Google Scholar 

  62. Van der Lee I, Postmus P, Smit E, et al. The activity of gemcitabine in patients with resistant small cell lung cancer (SCLC): A phase II study. Proc Am Soc Clin Oncol 18:476a, 1999 (abstract 1835).

    Google Scholar 

  63. Humblet Y, Symann M, Bosly A, et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: A randomized study. J Clin Oncol 5(12):1864–1873, 1987.

    PubMed  CAS  Google Scholar 

  64. Goodman GE, Crowley J, Livingston RB, et al. Treatment of limited small-cell lung cancer with concurrent etoposide/cisplatin and radiotherapy followed by intensification with high-dose cyclophosphamide: A Southwest Oncology Group study. J Clin Oncol 9(3):453–457, 1991.

    PubMed  CAS  Google Scholar 

  65. Elias AD, Avash L, Frei E 3d, et al. Intensive combined modality therapy for limited-stage small-cell lung cancer. J National Cancer Institute 85(7):559–566, 1993.

    Article  CAS  Google Scholar 

  66. Rizzo D, Stiff P, Elias A. Autologous stem cell transplantation for small cell lung cancer. Proc Am Soc Clin Oncol 18:469a, 1999 (abstract 1811).

    Google Scholar 

  67. Smit EF, Postmus PE. A phase II study of oral etoposide 100 mg/day for 21 days every 4 weeks in untreated elderly and poor performance status small cell lung cancer patients. Cancer Treat Res 7:136, 1991 (abstract).

    Google Scholar 

  68. Doward AJ. A prospective study of low dose oral etoposide in poor prognosis small cell lung cancer. Cancer Treat Res 7:111, 1991 (abstract).

    Google Scholar 

  69. Medical Reserch Council Lung Cancer Working Party. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicentre randomised trial. Lancet 348:563–566, 1996.

    Google Scholar 

  70. Harper P, Underhill C, Ruiz de Elvira MC, et al. A randomized study of oral etoposide versus combination chemotherapy in poor prognosis small cell lung cancer. Proc Am Soc Clin Oncol 15:27, 1996 (abstract).

    Google Scholar 

  71. Johnson DH, Greco FA, Strupp J, et al. Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: A phase II trial. J Clin Oncol 8:1613, 1990.

    PubMed  CAS  Google Scholar 

  72. Einhorn LH, Bond WH, Hornback N, et al. Phase II trial of oral VP-16 in refractory small cell lung cancer: A Hoosier Oncology Group study. Semin Oncol 17:32, 1990.

    PubMed  CAS  Google Scholar 

  73. von Pawel J and von Roemeling R. Survival benefit from tirazoneTM (tirapazamine) and cisplatin in advanced non-small cell lung cancer (NSCLC) patients: Final results from the international phase III Catapult I trial. Proc Am Soc Clin Oncol 17:454A, 1998 (abstract 1749).

    Google Scholar 

  74. Kane MA and Bunn PA Jr (eds). Biology of lung cancer. Marcel Dekker Inc, New York, 1998.

    Google Scholar 

  75. Stetler-Stevenson W, Aznavovoorian S, Liotta LA. Tumour cell interactions with the extracellular matrix during invasion and metastasis. Cell Biol 9:541–573, 1993.

    Article  CAS  Google Scholar 

  76. Chambers AF, Matrisian LM. Changing views of the role of metalloproteinases in metastasis. J Natl Cancer Inst 89:1260–1270, 1997.

    Article  PubMed  CAS  Google Scholar 

  77. Michael M, Babic B, Khokha R, et al. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol 17(6):1802–1808, 1999.

    PubMed  CAS  Google Scholar 

  78. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 15:62–75, 1997.

    Article  Google Scholar 

  79. Wojtowicz-Praga S, Toni J, Johnson M, et al. Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 16(6):2150–2156, 1998.

    PubMed  CAS  Google Scholar 

  80. Jones DA, Cummings J, Langdon SP and Smyth JF. Preclinical studies on the broad-spectrum neuropeptide growth factor antagonist G. Gen Pharmac 28(2):183–189, 1997.

    Article  CAS  Google Scholar 

  81. MacKinnon AC, Armstrong RA, Waters CM, et al. [Arg6D-Trp79N ePheB]substance P (6–11) activates JNK and induces apoptosis in small cell lung cancer cells via an oxidant-dependent mechanism. Br J Cancer 80(7):1026–1034, 1999.

    Article  PubMed  CAS  Google Scholar 

  82. Kalemkerian GP, Jasti RK, Celano P, et al. All-trans-retinoic acid alters myc gene expression and inhibits in vitro progression in small cell lung cancer. Cell Growth & Differentiation 5(1):55–60, 1994.

    CAS  Google Scholar 

  83. Kalemkerian GP, Jiroutek M, Ettinger DS, et al. A phase II study of all-transretinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung cacrincoma: An Eastern Cooperative Oncology Group study. Cancer 83(6):1102–1108, 1998.

    Article  PubMed  CAS  Google Scholar 

  84. Kalemkerian GP, Ou X, Adil MR, et al. Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: Induction of apoptosis and bcl-2 modification. Cancer Chemotherapy & Pharmacology 43(6):507–515, 1999.

    Article  CAS  Google Scholar 

  85. Ziegler A, Luedke GH, Fabbro D, et al. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the bcl-2 coding sequence. J Natl Cancer Inst 89(14):1027–1036, 1997.

    Article  PubMed  CAS  Google Scholar 

  86. Swisher SG, Roth JA, Nemunaitis J, et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 91(9):763–771,1999.

    Article  PubMed  CAS  Google Scholar 

  87. Ookawa K, Shiseki M, Takahashi R, et al. Reconstitution of the RB gene suppresses the growth of small-cell lung carcinoma cells carrying multiple genetic alterations. Oncogene 8(8):2175–2181, 1993.

    PubMed  CAS  Google Scholar 

  88. McCracken JD, Chen T, White J, et al. Combination chemotherapy, radiotherapy, and BCG immunotherapy in limited small-cell carcinoma of the lung: A Southwest Oncology Group study. Cancer 49(11):2252–2258, 1982.

    Article  PubMed  CAS  Google Scholar 

  89. Jackson DV Jr, Paschal BR, Ferree C, et al: Combination chemotherapy-radiotherapy with and without the methanol-extraction residue of Bacillus Calmette-Guerin (MER) in small cell carcinoma of the lung: A prospective randomized trial of the Piedmont Oncology Association. Cancer 50(1):48–52, 1982.

    Article  PubMed  Google Scholar 

  90. Mattson K, Niiranen A, Pryhonen S, etai.Natural interferon alfa as maintenance therapy for small cell lung cancer. European J Cancer 28A(8–9):1387–1391,1992.

    Article  CAS  Google Scholar 

  91. Mattson K, Niiranen A, Ruotsalainen T, et al. Interferon maintenance therapy for small cell lung cancer: Improvement in long-term survival. J Interferon & Cytokine Research 17(2):103–105, 1997.

    Article  CAS  Google Scholar 

  92. Kelly K, Bunn PA Jr, Crowley J, et al. The role of alfa interferon (r-IFN 2a) maintenance in patients with limited stage SCLC responding to concurrent chemoradiation: A Southwest Oncology Group study (SWOG). J Clin Oncol 13:2924–2930, 1995.

    PubMed  CAS  Google Scholar 

  93. LeBeau B, de la Salmoniere P, Ozenne G, et al. alnterferon (aIFN) as maintenance therapy for small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 18:475a, 1999 (abstract 1832).

    Google Scholar 

  94. Ruotsalainen TM, Halme M, Tamminen K, et al. Concomitant chemotherapy and IFN-alpha for small cell lung cancer: A randomized multicenter phase III study. Journal of Interferon & Cytokine Research 19(3):253–259, 1999.

    Article  CAS  Google Scholar 

  95. Chapman PB, Houghton AN. Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody. J Clinical Investigation 88(1):186–192, 1991.

    Article  CAS  Google Scholar 

  96. McCaffery M, Yao TJ, Williams L, et al. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: Enhanced immunogenicity when combined with adjuvant. Clinical Cancer Research 2(4):679–686, 1996.

    PubMed  CAS  Google Scholar 

  97. Grant SC, Kris MG, Houghton AN, Chapman PB. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clinical Cancer Resarch 5(6):1319–1323, 1999.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Colorado Cancer Center, Denver, CO 80220, USA

    Karen Kelly M.D.

Authors
  1. Karen Kelly M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Johns Hopkins Oncology Center, Bunting Blaustein Cancer Research Building, Baltimore, Maryland, USA

    David S. Ettinger MD

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Kelly, K. (2001). Treatment of Extensive Stage Small Cell Lung Cancer. In: Ettinger, D.S. (eds) Thoracic Oncology. Cancer Treatment and Research, vol 105. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1589-0_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-1589-0_10

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5629-5

  • Online ISBN: 978-1-4615-1589-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation